Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and liver transplant

Heijerman, 2019, Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial, Lancet, 394, 1940, 10.1016/S0140-6736(19)32597-8 Middleton, 2019, Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele, N Engl J Med, 381, 1809, 10.1056/NEJMoa1908639 Sasame, 2022, The impact of liver disease on mortality in cystic fibrosis-A systematic review, J Cyst Fibros, 21, 202, 10.1016/j.jcf.2021.07.014 Toledano, 2019, The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study, PLoS ONE, 14, 10.1371/journal.pone.0212779 Thavamani, 2022, Cystic fibrosis-related liver disease is an independent risk factor for mortality and increased health care resource utilization in hospitalized pediatric patients with cystic fibrosis, Pediatr Pulmonol, 57, 1717, 10.1002/ppul.25941 NHSBT data, personal communication 2022. Rhiannon Taylor (nhsbt.nhs.uk). Milkiewicz, 2002, Transplantation for cystic fibrosis: outcome following early liver transplantation, J Gastroenterol Hepatol, 17, 208, 10.1046/j.1440-1746.2002.02671.x Viswanathan, 2022, Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment, Eur J Drug Metab Ph, 47, 817, 10.1007/s13318-022-00791-8 Salehi, 2021, Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio), Respir Med Case Rep, 34 McKinzie, 2022, Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis, J Cyst Fibros, 21, 227, 10.1016/j.jcf.2021.07.017 Ragan, 2022, The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: a case series, Pediatr Pulmonol, 57, 411, 10.1002/ppul.25779 Ramos, 2022, Use of elexacaf tor/tezacaf tor/ivacaf tor among cystic fibrosis lung transplant recipients, J Cyst Fibro, 21, 745, 10.1016/j.jcf.2022.04.009 Choong, 2022, Therapeutic drug monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in cystic fibrosis: where are we now?, Pharmaceutics, 14, 10.3390/pharmaceutics14081674 Spoletini, 2022, Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis, J Cyst Fibros, 21, 1061, 10.1016/j.jcf.2022.05.001